The opioid epidemic is the most important and most serious public health crisis today. The effects are reported in overdose deaths but are also starkly evident in declines in sense of well-being and general health.
As per most recent research, JEC analysis has found that the opioid epidemic has cost the U.S. nearly $1.5 trillion in 2020, and this figure is likely increasing each year! The problem is so dire that Congress has approved $10.6 billion in discretionary spending to combat the epidemic.
Scilex Holding Company (NASDAQ: SCLX) is a revenue-generating company that is focused on addressing one of the biggest issues facing humanity today - the overuse of opioids. The company is focused on developing non-opioid pain management products that provide the relief patients so desperately need, while avoiding the debilitating addiction that often comes with the use of opioids.
Roughly 112,000 Americans died in 2023 from overdoses, and it is probable that a good number of those involved opioid use at some point to reduce physical pain of various types.
Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and becoming the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products that maximize quality of life.
Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly owned subsidiaries.
Scilex Pharmaceuticals, Inc. has three FDA-approved commercial products on the market and 3X version follow-on product, SP-103, is the next generation of ZTlido®:
The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief.
The company acquired two FDA approved non-opioid pain products, GLOPERBA® and ELYXYB®. GLOPERBA® is indicated for the prophylaxis of gout flares in adults. Elyxyb is indicated for the acute treatment of migraine with or without aura in adults. We launched ELYXYB® in the U.S. in April 2023 , GLOPERBA® was launched on June 10th, 2024.
ZTlido is the #1 prescribed branded non-opioid analgesic by the pain specialist! Over 1MM patients have been treated with ZTlido as of last year. According to market research, patient satisfaction with ZTlido was ~90%.
ZTlido Q2-2024 Sales Performance –
Based on the independent market research conducted by Syneos Health Consulting, with the new campaign, health care providers (HCPs) report increased awareness and substantial intent to utilize for ZTlido® with peak sales potential projected to reach over $500 million in the next 6 years in the U.S.!
The company believes that its products and product candidates have the potential to provide effective non-opioid prescription pain medication options for patients and healthcare providers who seek alternatives to opioids and NSAIDs for various pain conditions.
FDA approval may come sooner than later for SP-103…
There has been a successful end of Phase II meeting with the FDA leading to an agreed path forward to NDA upon completion of Phase III trials for the blockbuster product candidate, SP-103, for the treatment of chronic neck pain associated with muscle spasms!
"We are very pleased with the end of Phase II meeting and received a clear path forward to NDA for our blockbuster product candidate, SP-103. SP-103 has the potential to meet our core goal of developing leading pain management therapies to significantly improve the lives of patients for the treatment of chronic neck pain associated with muscle spasms who are seeking new effective treatments. We are looking forward to conducting Phase 3 trials and believe that Scilex is the only company with technology allowing much higher lidocaine concentration than any other topical lidocaine system treatments. Higher concentration of a drug per covered area of skin is important for achieving therapeutic response.” - Dmitri Lissin, M.D., Chief Medical Officer of Scilex.
The mission of SCLX’s management team is to bolster our proprietary pain management clinical pipeline and technology by employing years of expertise that come with Pain Management Products, Clinical Pipeline, and technology. These seasoned professionals bring a type of leadership that is unmatched in the pharmaceutical industry!
Jaisim Shah - Chief Executive Officer & President
Jaisim Shah has over 30 years industry success in leading product development & commercializing innovative therapies and creating companies with documented success in development and commercialization of some of today’s most recognized pharmaceutical brands.
Henry Ji, PhD - Executive Chairman
Henry Ji brings 25+ years of experience in the biotechnology and life sciences industry. Dr. Ji has been Chairman of Scilex from March 2019 to present and served as the CEO of Scilex Pharmaceuticals from November 2016 to March 2019.
Suketu D. Desai, PhD - Chief Technical Officer & Senior Vice President
Suketu D. Desai, Ph.D. has 25+ years of experience in the Biologics and Pharmaceutical Industry. Suketu is Chief Technical Officer and Senior Vice President, Chemistry, Manufacturing and Controls, Regulatory CMC, and Quality Assurance at Scilex Pharmaceuticals (2015 – present).
Dmitri Lissin, MD - Chief Medical Officer & Senior Vice President
Dmitri Lissin currently serves as Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs of Scilex/Semnur Pharmaceuticals (2015 – present).
Suresh Khemani - Chief Commercial Officer & Senior Vice President
Mr. Khemani brings more than 25 years of global pharmaceutical experience to Scilex, a privately held clinical development and commercial company based in Palo Alto, California.
Steve Lincoln - General Counsel & Chief Compliance Officer
Steve Lincoln serves as General Counsel, Chief Compliance Officer for Scilex Holding Company. Steve has been involved in the biopharma industry for more than 21 years.
Stephen Ma - Chief Financial Officer & Senior Vice President
Stephen Ma has served as the Company’s Chief Accounting Officer since November 2022 and previously served as its Vice President of Finance from January 2022 to November 2022.
Elaine K Chan, PharmD - Executive Director and Head of Medical Affairs
Dr. Elaine Chan heads Medical Affairs at Scilex, since 2022. Prior to joining Scilex, Dr. Chan was Senior Director at Genentech Inc (a member of the Roche group), one of the world’s leading pharmaceutical companies, from 2009 to 2021, where she held wide-ranging roles in Medical Affairs, Business Operations and Strategy, Pharmacovigilance, Marketing and new product planning.
Gigi DeGuzman - Senior Executive Director and Chief of Staff
Gigi DeGuzman is a seasoned professional with over 25 years of experience in human resources, operations management, facilities management, event planning, executive coordination, and administrative operations.
Mike Ciaffi - National Sales Director
Mike has over 25 years in the pharmaceutical industry. Mike currently serves as the National Sales Director at Scilex Holding Company. Mike joined Scilex in 2018 as a Regional Business Director to build a sales team to launch ZTLido (Lidocaine Topical System) 1.8%.
Sumant Rajendran - Executive Director of Marketing
Sumant Rajendran heads up the Marketing department and brings over 20 years’ experience to Scilex. He has been at the company since mid-2019 and has overseen the growth of our marketed portfolio from one product (ZTlido) to three (with the addition of Elyxyb and Gloperba).
Scilex Holding Company (NASDAQ: SCLX) is a small cap NASDAQ firm that is an innovative leader in non-opioid pain therapeutics. The company’s offerings could significantly aid in stopping the opioid crisis and create maximum shareholder growth!
To reiterate the company’s investment highlights:
Not long ago SCLX also announced the closing of a financing deal that may bolster the company’s financial position and position the company for future growth.
With a substantial short position on SCLX currently, there could be a massive short squeeze on the horizon.
Short squeeze has become a buzzword in the investment world after the skyrocketing of GameStop Corp. and AMC Entertainment Holdings Inc. stock hit global media headlines.
The short squeeze of AMC Entertainment Holdings Inc. (NYSE: AMC) stock occurred in 2021. According to S3 Partners, about 20% of all the US cinema chain’s shares were traded in short positions at that time. Note that on average this figure is equal to 5%. This large volume of selling positions triggered a short squeeze: on 4 January 2021, AMC Entertainment stock traded at the price of 2.01 USD per share; while during the trading session on 2 June, it reached 72.62 USD. The share price skyrocketed 3512.94% in half a year.
We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Huge Alerts nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on Huge Alerts. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Huge Alerts makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website.
Some of the content on this website contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which may be beyond a company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. It is hereby noted that forward-looking statements contained herein may include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. A company’s actual performance could greatly differ from those described in any forward-looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company’s products; the company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, a company’s past performance does not guarantee future results.
Generally, the information regarding a company profiled or discussed on this website is provided from public sources hugealerts.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Huge Alerts has no obligation to update any of the information provided. Huge Alerts, its owners, officers, directors, contractors and employees are not responsible for errors and omissions.
From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. Huge Alerts encourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content.Huge Alerts, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Huge Alerts control, endorse, or guarantee any content found in such sites. Huge Alerts does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that Huge Alerts, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Huge Alerts, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. Huge Alerts uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm.
Income Disclaimer
Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success, and are not responsible for your actions.
Huge Alerts has been retained by CDMG inc to perform promotional and advertising services for a limited time with respect to the company we are profiling or discussing on this website and in exchange for such services has received cash compensation from CDMG Inc . Questions regarding this website may be sent to editor@hugealerts.com
Huge Alerts has been compensated by CDMG Inc for the total sum of $350,000.00 This agreement is for the marketing of Scilex Holdings (NASDAQ:SCLX) which services include the issuance of this release and other opinions that we release concerning of Scilex Holdings (NASDAQ:SCLX). Huge Alerts has not investigated the background of CDMG Inc the hiring party, or Scilex Holdings (NASDAQ:SCLX) Anyone viewing this newsletter should assume CDMG Inc or affiliates of CDMG inc own shares of Scilex Holdings (NASDAQ:SCLX) which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. Huge Alerts has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding Scilex Holdings (NASDAQ:SCLX)